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A B S T R A C T
Background
Irritable bowel syndrome (IBS) is a common, chronic disorder that leads to decreased health-related quality of life and work productivity.
A previous version of this review was not able to draw firm conclusions about the effectiveness of homeopathic treatment for IBS and
recommended that further high quality RCTs were conducted to explore the clinical and cost effectiveness of homeopathic treatment for
IBS. Two types of homeopathic treatment were evaluated in this systematic review: 1. Clinical homeopathy where a specific remedy is
prescribed for a specific condition; 2. Individualised homeopathic treatment, where a homeopathic remedy based on a person's individual
symptoms is prescribed after a detailed consultation.
Objectives
To assess the effectiveness and safety of homeopathic treatment for IBS.
Search methods
For this update we searched MEDLINE, CENTRAL, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Allied and
Complementary Medicine Database (AMED), the Cochrane IBD Group Specialised Register and trials registers from inception to 31 August
2018.
Selection criteria
Randomised controlled trials (RCTs), cohort and case-control studies that compared homeopathic treatment with placebo, other control
treatments, or usual care, in adults with IBS were considered for inclusion.
Data collection and analysis
Two authors independently assessed the risk of bias and extracted data. The primary outcome was global improvement in IBS as measured
by an IBS symptom severity score. Secondary outcomes included quality of life, abdominal pain, stool frequency, stool consistency, and
adverse events. The overall certainty of the evidence supporting the primary and secondary outcomes was assessed using the GRADE
criteria. We used the Cochrane risk of bias tool to assess risk of bias. We calculated the mean difference (MD) and 95% confidence interval
(CI) for continuous outcomes and the risk ratio (RR) and 95% CI for dichotomous outcomes.
Main results
Four RCTs (307 participants) were included. Two studies compared clinical homeopathy (homeopathic remedy, asafoetida or asafoetida
plus nux vomica) to placebo for IBS with constipation (IBS-C). One study compared individualised homeopathic treatment (consultation
plus remedy) to usual care for the treatment of IBS in female patients. One study was a three armed RCT comparing individualised home-
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opathic treatment to supportive listening or usual care. The risk of bias in three studies (the two studies assessing clinical homeopathy
and the study comparing individualised homeopathic treatment to usual care) was unclear on most criteria and high for selective report-
ing in one of the clinical homeopathy studies. The three armed study comparing individualised homeopathic treatment to usual care and
supportive listening was at low risk of bias in four of the domains and high risk of bias in two (performance bias and detection bias).
A meta-analysis of the studies assessing clinical homeopathy, (171 participants with IBS-C) was conducted. At short-term follow-up of two
weeks, global improvement in symptoms was experienced by 73% (46/63) of asafoetida participants compared to 45% (30/66) of placebo
participants (RR 1.61, 95% CI 1.18 to 2.18; 2 studies, very low certainty evidence). In the other clinical homeopathy study at two weeks, 68%
(13/19) of those in the asafoetida plus nux vomica arm and 52% (12/23) of those in the placebo arm experienced a global improvement
in symptoms (RR 1.31, 95% CI 0.80 to 2.15; very low certainty evidence). In the study comparing individualised homeopathic treatment to
usual care (N = 20), the mean global improvement score (feeling unwell) at 12 weeks was 1.44 + 4.55 (n = 9) in the individualised homeo-
pathic treatment arm compared to 1.41 + 1.97 (n=11) in the usual care arm (MD 0.03; 95% CI -3.16 to 3.22; very low certainty evidence).
In the study comparing individualised homeopathic treatment to usual care, the mean IBS symptom severity score at 6 months was 210.44
+ 112.4 (n = 16) in the individualised homeopathic treatment arm compared to 237.3 + 110.22 (n = 60) in the usual care arm (MD -26.86,
95% CI -88.59 to 34.87; low certainty evidence). The mean quality of life score (EQ-5D) at 6 months in homeopathy participants was 69.07
(SD 17.35) compared to 63.41 (SD 23.31) in usual care participants (MD 5.66, 95% CI -4.69 to 16.01; low certainty evidence).
For In the study comparing individualised homeopathic treatment to supportive listening, the mean IBS symptom severity score at 6
months was 210.44 + 112.4 (n = 16) in the individualised homeopathic treatment arm compared to 262 + 120.72 (n = 18) in the supportive
listening arm (MD -51.56, 95% CI -129.94 to 26.82; very low certainty evidence). The mean quality of life score at 6 months in homeopathy
participants was 69.07 (SD 17.35) compared to 63.09 (SD 24.38) in supportive listening participants (MD 5.98, 95% CI -8.13 to 20.09; very
low certainty evidence).
None of the included studies reported on abdominal pain, stool frequency, stool consistency, or adverse events.
Authors' conclusions
The results for the outcomes assessed in this review are uncertain. Thus no firm conclusions regarding the effectiveness and safety of
homeopathy for the treatment of IBS can be drawn. Further high quality, adequately powered RCTs are required to assess the efficacy and
safety of clinical and individualised homeopathy for IBS compared to placebo or usual care.
P L A I N   L A N G U A G E   S U M M A R Y
Homeopathy for treatment of irritable bowel syndrome
What is irritable bowel syndrome?
Irritable bowel syndrome (IBS) is a common chronic disorder where a person experiences the following symptoms: abdominal pain, dis-
comfort, bloating, constipation or diarrhoea or both. It is difficult to treat because different people experience different symptoms. Some
people experience constipation as the main symptom, this form of IBS is known as IBS-C, while others experience diarrhoea as the main
symptom. This form of IBS is known as IBS-D. Others experience both constipation and diarrhoea, this form of IBS is known as IBS-M where
the M stands for mixed. Currently there is no agreement on the best form of treatment for IBS.This means that it is important to evaluate
the effectiveness and safety of treatments, including homeopathic treatment, which some IBS sufferers use.
What is homeopathy?
There are different types of homeopathy. Clinical homeopathy matches a 'remedy' to a specific condition, such as IBS and everybody
who has that condition would be given the same remedy. Individualised homeopathy involves a series of in-depth consultations to assess
symptoms and other issues that may affect the patient. Following an in-depth consultation the homeopath will select the most appropriate
remedy based on the persons' individual symptoms. Individualised homeopathy includes both a consultation and a remedy, whereas
clinical homeopathy consists of a remedy without the in-depth consultation.
What did the researchers investigate?
The researchers investigated whether homeopathic treatment led to the improvement of the symptoms of IBS in people with IBS. The
researchers
What did the researchers find?
Four randomised controlled trials (RCTs) with 307 participants with IBS were included. Two RCTs (129 participants) compared a homeo-
pathic remedy (asafoetida and asafoetida plus nux vomica) to a placebo remedy for the treatment of people with IBS-C. One study (23
participants) compared individualised homeopathic treatment to usual care in female patients diagnosed with IBS. One study (94 partic-
ipants) was a three armed study comparing individualised homeopathic treatment plus usual care, supportive listening plus usual care
and usual care.
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The four trials tested the effects of homeopathic treatment on the severity of IBS symptoms. No conclusions can be drawn from the RCT
comparing individualised homeopathic treatment to usual care due to the small number of participants and the low quality of reporting
in this trial. This study was carried out in 1990 and usual care for IBS may have changed since then making the results difficult to compare
to current treatments.
No conclusions can be drawn from the three armed study comparing individualised homeopathic treatment plus usual care, supportive
listening plus usual care and usual care due to the small number of participants in the homeopathic treatment arm (n=16).
The results of two small studies were combined (129 participants) and this suggested that there may be a possible benefit for clinical
homeopathy, using the remedy asafoetida, over placebo for patients with IBS-C at a short-term follow-up of two weeks. However both of
the studies were carried out in the 1970s when the reporting of trials was not as comprehensive as it is now and we are very uncertain
about these results and cannot suggest a possible benefit for clinical homeopathy.
Conclusions
The results for the outcomes assessed in this review are uncertain. Thus no firm conclusions regarding the effectiveness and safety of
homeopathy for the treatment of IBS can be drawn. Further high quality RCTs enrolling larger numbers of patients are required to assess
the effectiveness and safety of clinical and individualised homeopathy for IBS.
Homeopathy for treatment of irritable bowel syndrome (Review)
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Summary of findings for the main comparison.   Homeopathy versus placebo
Homeopathy versus placebo for the treatment of irritable bowel syndrome
Patient or population: patients with irritable bowel syndrome
Settings: outpatients
Intervention: homeopathy
Illustrative comparative
risks* (95% CI)
Outcomes
Risk with
placebo
Risk with
homeopathy
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Global improvement
(Asafoetida subgroup)
Follow-up: 2 weeks
455 per 1000 732 per 1000
(536 to 991)
RR 1.61 
(1.18 to 2.18)
129
(2 studies)
⊕⊝⊝⊝
very low1,2,3
Global improvement defined as
self improvement on a 3 point
Likert scale
Global improvement
(Asafoetida + nux vom sub-
group)
Follow-up: 2 weeks
522 per 1000 683 per 1000
(417 to 1000)
RR 1.31 
(0.8 to 2.15)
42
(1 study)
⊕⊝⊝⊝
very low1,3,4
Global improvement defined as
self improvement on a 3 point
Likert scale
Quality of life Not reported This outcome was not reported
Abdominal pain Not reported This outcome was not reported
Stool frequency Not reported This outcome was not reported
Stool consistency Not reported This outcome was not reported
Adverse events Not reported This outcome was not reported
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
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Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded one level due to high risk of bias
2 Downgraded one level due to sparse data (76 events)
3 Downgraded one level due to the endpoint time (2 weeks). Given the long term nature of IBS it is not clear how useful a two week outcome is for patients' and clinicians'
decision making.
4 Downgraded two levels due to very sparse data ( 25 events)
 
 
Summary of findings 2.   Homeopathy versus usual care
Homeopathy versus usual care for the treatment of irritable bowel syndrome
Patient or population: patients with irritable bowel syndrome
Settings: outpatients
Intervention: homeopathy
Illustrative comparative
risks* (95% CI)
Assumed risk Correspond-
ing risk
Outcomes
Usual care Homeopathy
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Global improve-
ment (Feeling un-
well)
Follow-up: 12
weeks
The mean
global im-
provement
score was 1.41
(SD = 1.97)
The mean
global im-
provement
score was 1.44
(SD = 4.55)
MD 0.03 high-
er (3.16 lower
to 3.22 higher)
- 20
(1 study)
⊕⊝⊝⊝
very low1,2
Global improvement de-
fined as a self reported im-
provement of symptoms.
Scale from: 0 to 5
Higher scores indicate
greater improvement
Quality of life Not reported This outcome was not re-
ported
Abdominal pain Not reported This outcome was not re-
ported
Stool frequency Not reported This outcome was not re-
ported
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Stool consistency Not reported This outcome was not re-
ported
Adverse events Not reported This outcome was not re-
ported
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded one level due to high risk of bias
2 Downgraded two levels due to very sparse data (20 participants)
 
 
Summary of findings 3.   Homeopathy plus usual care versus usual care
Homeopathy plus usual care versus usual care for the treatment of irritable bowel syndrome
Patient or population: patients with irritable bowel syndrome
Settings: outpatients
Intervention: homeopathy
Illustrative comparative risks* (95%
CI)
Assumed risk Corresponding risk
Outcomes
Control Homeopathy
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Global improve-
ment (IBS-SSS)
Follow-up: 6
months
The mean
global im-
provement
score was
237.3 (SD =
110.27)
The mean global im-
provement score was
210.44 (SD = 112.4)
MD 26.86 lower (88.59
lower to 34.87 higher)
- 76
(1 study)
⊕⊕⊝⊝
low1,2
IBS-SSS. Scale from: 0 to
400
Lower scores indicate less
severe disease
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Quality of life
Follow-up 6
months
The mean
quality of life
score was
63.41 (SD =
23.31)
The mean quality of
life score was 69.07 (SD
= 17.35)
MD 5.66 higher (4.69
lower to 16.01 higher)
- 76
(1 study)
⊕⊕⊝⊝
low1,2
EQ-5D
Higher scores indicate
better quality of life
Abdominal pain Not reported This outcome was not re-
ported
Stool frequency Not reported This outcome was not re-
ported
Stool consisten-
cy
Not reported This outcome was not re-
ported
Adverse events Not reported This outcome was not re-
ported
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded one level due to sparse data (76 participants)
2 Downgraded one level due to high risk of bias
 
 
Summary of findings 4.   Homeopathy plus usual care versus supportive listening plus usual care
Homeopathy plus usual care versus supportive listening plus usual care for treatment of irritable bowel syndrome
Patient or population: patients with irritable bowel syndrome
Settings: outpatients
Intervention: Homeopathy
Outcomes Illustrative comparative risks* (95%
CI)
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
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Assumed risk Corresponding risk
Control Homeopathy
Global improve-
ment (IBS-SSS)
Follow-up: 6
months
The mean
global im-
provement
score was 262
(SD = 120.72)
The mean global im-
provement score was
210.44 (SD = 112.4)
MD 51.56 lower
(129.94 lower to
26.82 higher)
- 34
(1 study)
⊕⊝⊝⊝
very low1,2
IBS-SSS. Scale from: 0 to
400
Lower scores indicate
less severe disease
Quality of life
Follow-up: 6
months
The mean
quality of life
score was
63.09 (SD =
24.38)
The mean quality of
life score was 69.07
(SD = 17.35)
MD 5.98 higher (8.13
lower to 20.09 high-
er)
- 34
(1 study)
⊕⊝⊝⊝
very low1,2
EQ-5D
Higher scores indicate
better quality of life
Quality of life Not reported This outcome was not
reported
Abdominal pain Not reported This outcome was not
reported
Stool frequency Not reported This outcome was not
reported
Stool consistency Not reported This outcome was not
reported
Adverse events Not reported This outcome was not
reported
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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B A C K G R O U N D
Description of the condition
Irritable bowel syndrome (IBS) is a common, chronic disorder that
affects 10 to 22% of the population in the UK (Williams 2007). The
economic costs of IBS in primary care in the UK are estimated to be
over GBP 200 million per year (Akehurst 2002). It is difficult to treat
because no single cause has been identified. Treatment is directed
at controlling symptoms, using pharmacological and non-pharma-
cological approaches (Ruepert 2011; Spiller 2007; Zijdenbos 2009).
IBS is characterised by recurrent symptoms (i.e. abdominal pain
or discomfort, bloating, constipation, or diarrhoea) that indicate a
dysfunctional gastrointestinal tract rather than an organic change
or specific diagnosis. It has an uncertain prognosis for recovery
(Mearin 2006). Such patients have a plethora of non-colonic symp-
toms such as back pain, urinary frequency, and chronic fatigue
which can lead to the patient being referred to the wrong special-
ty and having inappropriate investigations and even surgery. This
can lower quality of life (Agrawal 2006; Longstreth 2007). In addi-
tion, sleep disturbance and depressed mood are common in IBS
patients.
Diagnosis of IBS can be made using the Rome IV criteria (Drossman
2016), although this is largely a research tool used to allow com-
mon reporting standards of symptoms in trials and other research
populations. In clinical practice the diagnosis of IBS is largely based
on symptoms and should be positive rather than by exclusion, al-
though the presence of alarm symptoms (e.g. blood in stool, weight
loss or family history) should prompt further investigations (Spiller
2007). IBS can be characterised into the following subtypes: IBS
with constipation, IBS with diarrhoea, IBS with mixed bowel habits
and unspecified.
Usual care for IBS commonly includes advice on lifestyle, includ-
ing diet and stress reduction, possibly combined with medication.
There are a number of different medications used to help treat
IBS: antispasmodic medicines, which help to reduce abdominal
pain and cramping; laxatives, which help to treat the symptoms
of constipation; anti-motility medicines, which help to treat the
symptoms of diarrhoea, and neuropathic modulators such as tri-
cyclic antidepressants, which were originally designed to treat de-
pression, but also help to reduce the feeling of abdominal pain
and cramping. Alternative treatments such as hypnotherapy, psy-
chotherapy and acupuncture have been tried and have a place in
selected patients (Agrawal 2006,McPherson 2012). However these
treatments have limited availability and are expensive and labour
intensive. Despite much research into both psychological and phar-
macological treatments for irritable bowel syndrome no consensus
exists on its optimal treatment (Ruepert 2011; Zijdenbos 2009).
Description of the intervention
Homeopathy is a popular, albeit controversial form of complemen-
tary and alternative medicine. A UK survey has shown that 1.9%
of the population consulted a homeopath in the 12 months prior
to the survey and 8.6% had bought an over-the-counter homeo-
pathic remedy (Thomas 2001). Homeopathy is based on treating
patients with remedies prepared from substances that have been
highly diluted and succussed (shaken). It was first developed by Sa-
muel Hahnemann in the eighteenth century in Germany and works
on the principle of “like cures like” whereby a substance that would
cause symptoms in a healthy person cures those same symptoms
in illness.
Homeopathic treatment varies among different practitioners and
four main types can be identified (Linde 1997):
• Individualised (or classical) homeopathy, the type most com-
monly practised in the UK, involves a consultation followed by
the prescription of a homeopathic medicine individualised to
the patient;
• Clinical homeopathy, where the same homeopathic medicine is
used for a group of patients all presenting with the same clinical
condition (e.g. lycopodium for IBS, arnica for bruising);
• Complex homeopathy, where a number of different homeopath-
ic medicines are given either in a fixed combination or concur-
rently; and
• Isopathy, where the homeopathic medicine is based on the sub-
stance which has led to the problem (e.g. grass pollen for hay
fever).
Homeopathic medicines when prescribed by trained professionals
are generally regarded as safe (Dantas 2000).
How the intervention might work
Homeopathy is based on the ‘law of similars’ i.e. a substance which
causes symptoms in a healthy individual can be used to treat
similar symptoms in a diseased person (Vithoulkas 1980).There is
significant debate regarding the scientific basis for homeopathy
amongst healthcare practitioners, scientists, politicians and policy
makers and the mechanism by which homeopathic remedies may
work is not completely understood.
The manufacture of homeopathic medicines involves serial dilu-
tion alternating with violent agitation (i.e. ‘succussion’). The com-
bination of these two processes is referred to as ‘potentisation’ or
‘sequential kinetic activation’ (Gariboldi 2009). Many homeopath-
ic medicines are diluted beyond Avogadro’s number and there-
fore fall under the classification of ultra-high dilutions (UHDs). Avo-
gadro's number is the number of molecules in a mole of a sub-
stance, approximately 6.0225 × 1023, which means that a sample
diluted beyond 1024 would have reached a stage where it is very un-
likely that there is even a single molecule of the original substance
present. The biological efficacy of UHDs may be dependent on se-
quential kinetic activation (Gariboldi 2009), but the mechanism by
which sequential kinetic activation enables a UHD to be biological-
ly active is unknown. A common theory is that it involves stable wa-
ter structures, created by interactions between molecules of the bi-
ological material and the water it is dissolved in, allowing the wa-
ter to retain information about the biological material (Montagnier
2009).
Why it is important to do this review
This review is an update of a previously published Cochrane review
on homeopathy for irritable bowel syndrome (Peckham 2012). The
original review marked a small step forward in establishing whether
or not homeopathy is an effective treatment for IBS; however due
to the small number of studies, age of the studies and methodolog-
ical limitations the original review provided only limited informa-
tion. This updated review is timely not only because of the passage
of time but also given the continued lack of effective treatments
for IBS and the sustained interest in homeopathy as a potential
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treatment option. Lower gastrointestinal tract disorders account
for one in 20 of all general practice consultations in the UK (Thomp-
son 2000). In addition, gastroenterology problems are the fourth
most common referral to National Health Service (NHS) homeo-
pathic hospitals (Spence 2005) and one of the eight most common
conditions treated by NHS homeopaths in general practice (Math-
ie 2006). The frequency with which people with IBS consult home-
opaths may be some indication of the value which they place on the
homeopathic approach. Homeopathic treatment may offer a treat-
ment strategy for patients with IBS, but at present it is not clear if
it offers any benefit.
O B J E C T I V E S
The objective of this systematic review is to assess the effectiveness
and safety of homeopathic treatment for IBS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing homeopathic
treatment with placebo or active comparators were considered for
inclusion regardless of blinding method, publication status and
language of publication. Quasi randomised studies were also con-
sidered for inclusion, where allocation was achieved by 'quasi-ran-
dom' methods such as alternation between treatment arms, year
of birth, month entered into study. Cohort and case-control studies
were also considered for inclusion.
Types of participants
All trials of patients with a diagnosis of IBS were eligible for inclu-
sion in this review regardless of age, gender, race, educational sta-
tus or duration of IBS. Trials which included IBS patients in whom
10% or more had unstable psychiatric disorders, ulcerative coli-
tis, Crohn's disease, bowel cancer and pregnant and breastfeeding
women were excluded from this review.
Types of interventions
Trials were included if one of the groups in the trial received any
type of homeopathic treatment involving the delivery of a home-
opathic remedy (either by a homeopath following a consultation
or studies where a homeopathic remedy was delivered without a
consultation) and the other received placebo, an active compara-
tor treatment, or no treatment.
Types of outcome measures
All trials that included any one of the following outcome measures
were included in the review.
Primary outcomes
The primary outcome was global improvement of symptoms (pa-
tient-reported or clinician-evaluated or both) as measured by a
global IBS symptom score (e.g. IBS Severity Scoring System (IBS-
SSS), Adequate Relief Measure, GI Symptom Rating Scale, Function-
al Bowel Disorder Severity Index or IBS Symptom Questionnaire).
Secondary outcomes
Secondary outcomes included:
• Quality of life as measured by validated quality of life mea-
sure e.g. EQ5D, SF36, IBS Quality of Life Measure, IBS Quality of
Life Questionnaire, Functional Digestive Disorder Quality of Life
Questionnaire, IBS Health Related Quality of Life Questionnaire;
• Abdominal pain, discomfort and distension;
• Stool frequency, bowel transit time;
• Stool consistency; and
• Adverse events.
Search methods for identification of studies
Electronic searches
The following electronic databases were searched from inception
to 31 August 2018:
The Cochrane Central Register of Controlled Trials (CENTRAL) on
the Cochrane Library, Ovid MEDLINE, EMBASE, the Cumulative In-
dex to Nursing and Allied Health Literature (CINAHL) and the Al-
lied and Complementary Medicine Database (AMED). The Cochrane
IBD/FBD Group Specialised Register, Clinical trials.gov and the
WHO International Clinical Trials Registry Platform (ICTRP) http://
www.who.int/ictrp/en/ were also searched.
Searching other resources
1. Reference searching
The reference lists for all identified studies were inspected for ad-
ditional studies.
2. Personal contact
The first author of each included study was contacted for informa-
tion regarding unpublished trials.
Data collection and analysis
Selection of studies
Two authors (EJP and SB) independently reviewed the titles and
abstracts of the studies identified by the literature search. Included
studies were assessed against the predefined inclusion criteria.
Data extraction and management
Two authors (EP and SB) independently extracted data from the in-
cluded studies. Authors were contacted to clarify any unclear data.
EP who is an author of one of the included studies was not involved
in the data extraction or assessment of the risk of bias for the study
that she was involved in the conduct of, GT extracted the data for
this study.
Assessment of risk of bias in included studies
Two authors (SB and GT) independently assessed the methodolog-
ical quality of included randomised trials using the Cochrane risk of
bias tool (Higgins 2011). The following items were assessed:
• sequence generation (i.e. was allocation sequence adequately
generated?);
• allocation sequence concealment (i.e. was allocation adequate-
ly concealed?);
• blinding (i.e. was knowledge of the allocated interventions ade-
quately prevented during the study?);
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• incomplete outcome data (i.e. were incomplete outcome data
adequately addressed?);
• selective outcome reporting (i.e. are reports of the study free of
suggestion of selective outcome reporting?); and
• other potential sources of bias (i.e. was the study apparently free
of other problems that could lead to a high risk of bias e.g. base-
line imbalances, evidence of carry-over in cross-over trials, com-
parability of groups in cluster trials).
It was intended that, based on these criteria the studies would be
subdivided into three categories:
1. Low risk of bias i.e. all quality criteria met;
2. Medium risk of bias i.e. one or more of the quality criteria partly
met; and
3. High risk of bias i.e. one or more of the quality criteria not met.
It was intended that the quality of quasi-randomised trials, non-
randomised trials, cohort and case control studies would be as-
sessed using a quality instrument designed for assessing the qual-
ity of non-randomised studies (Downs 1998).
Using the GRADE (Grading of Recommendations Assessment, De-
velopment and Evaluation) approach (Atkins 2004, Schünemann
2011), we will assess the overall quality of the evidence supporting
the following outcomes: global improvement of symptoms, quality
of life, improvement in abdominal pain, stool frequency, stool con-
sistency and adverse events. The summary of the evidence will be
presented in a 'Summary of findings’ table, which will provide key
information about the best estimate of the magnitude of the effect
for each relevant comparison, and the rating of the overall confi-
dence in effect estimates for each outcome. The GRADEpro Guide-
line Development Tool will be used to create the 'Summary of find-
ings’ table.
Measures of treatment e>ect
Review Manager (RevMan 5.3.5) was used to analyse the data. For
continuous outcomes the mean difference (MD) with 95% confi-
dence interval (95% CI) was calculated. For each dichotomous out-
come the risk ratio (RR) with 95% CI was calculated.
Unit of analysis issues
We did not anticipate any unit of analysis issues arising from clus-
ter randomisation. In the case of multiple intervention groups each
intervention group was analysed separately against the control
group and the sample size for the control group was divided pro-
portionately across each intervention group. We noted that if the
results were reported at multiple time points in the studies, each
outcome would be analysed at pre-defined periods of follow-up in
separate meta-analyses. Time points would be grouped as follows:
less than three months, three months to one year, longer than one
year. These time points were chosen as representing time frames in
which a difference in the likelihood of responding could be expect-
ed.
Dealing with missing data
We intended to analyse data using the intention to treat (ITT) prin-
ciple and sensitivity analyses were to be undertaken as appropri-
ate (e.g. ITT versus available case, and study quality). However, da-
ta were analysed on an available case basis as the included studies
did not provide enough detail to allow for an ITT analysis.
Assessment of heterogeneity
Statistical heterogeneity was assessed using the Chi2 test and the
I2 statistic. If heterogeneity existed between studies (I2 ≥ 50%) for
the primary outcome, reasons for the heterogeneity would be ex-
plored. Clinical heterogeneity would be assessed through the de-
scription of the setting and homeopathic approach used in each
study.
Assessment of reporting biases
In the protocol we noted that if more than 10 studies were identified
for inclusion in this review, funnel plots would be used to assess
publication biases.
Data synthesis
Data from individual trials were combined by meta-analysis if the
interventions, outcomes and patient groups were sufficiently sim-
ilar (determined by consensus). For continuous data the MD with
95% CI was calculated where the same scales have been used.
Where studies were deemed sufficiently similar but different scales
have been used the standardised mean difference (SMD) would be
used to combine data. For dichotomous outcomes the pooled RR
and 95% CI were calculated.
In the protocol we specified that data would not be pooled for
meta-analysis if a high degree of heterogeneity (I2 > 75%) was de-
tected. A fixed-effect model would be used to pool data in the ab-
sence of heterogeneity. An I2 ≥ 50% is considered to represent mod-
erate heterogeneity and in such cases (I2 50 to 75%) a random-ef-
fects model would be used for pooling the data.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was planned between studies that prospective-
ly identified IBS patients using ROME III criteria versus studies that
did not use ROME III criteria to prospectively identify IBS patients.
In the protocol we also noted that if data were reported separately
for the different forms of IBS then a subgroup analysis comparing
the different forms would be carried out. A subgroup analysis was
also planned for quasi and true randomisation, different compara-
tors (e.g. no treatment, usual care, placebo, or other active treat-
ment) and different homeopathy interventions (e.g. individualised
or clinical homeopathy).
Sensitivity analysis
In the protocol we noted that if a sufficient number of trials were
identified a sensitivity analysis would be carried out by study quali-
ty to determine if the results of the primary analysis change accord-
ing to which trials are incorporated into the analysis.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of ex-
cluded studies and Characteristics of ongoing studies.
Results of the search
Figure 1 shows details of the search and selection process. From
citations initially identified, full text sources were examined (after
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removal of duplicates and assessment of abstract), studies were
excluded for various reasons (listed in the excluded studies table)
and four studies plus two secondary publications from two includ-
ed studies were included in the review (Owen 1990; Peckham 2014;
Rahlfs 1976; Rahlfs 1979). Two studies were included in quantita-
tive synthesis (Rahlfs 1976; Rahlfs 1979). No cohort or case-control
studies were identified.
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Figure 1.   Study flow diagram.
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Included studies
Four studies with a total of 307 participants were included (Owen
1990; Peckham 2014; Rahlfs 1976; Rahlfs 1979). See Characteris-
tics of included studies. Owen 1990 and Peckham 2014 were con-
ducted in the UK and published in English. Rahlfs 1976 and Rahlfs
1979 were conducted in the former Federal Republic of Germany
and published in German and were translated from German into
English. Rahlfs 1976, was a three arm trial comparing asafoetida
against asafoetida + nux vomica, against placebo, whereas Rahlfs
1979 compared asafoetida versus placebo (the participants in the
two trials are independent). The authors noted that Rahlfs 1976
failed to recruit its target number of participants, hence the (simpli-
fied) trial being re-run. There were 23 participants in Owen 1990, 72
participants in Rahlfs 1976, 119 participants in Rahlfs 1979 and 94
participants in Peckham 2014. All included studies were published
as full articles.
Owen 1990 compared individualised homeopathic treatment,
which involved a homeopathic consultation and an individualised
homeopathic remedy, to usual care which consisted of high doses
of dicyclomine hydrochloride, faecal bulking agents and diet sheets
asking the patient to take a high fibre diet. This study differs from
other pragmatic trials of individualised homeopathic treatment,
where the more common approach has been to compare individu-
alised homeopathic treatment plus usual care to usual care alone.
In Owen 1990 participants were asked to rate how unwell they felt
before and after treatment, exact details of how this was scored are
not given. Although Owen 1990 did not include a global measure-
ment of IBS as one of the outcomes, we considered the rating of
how unwell patients felt to provide a global measurement of the pa-
tients' health. The other outcome measures in Owen 1990 involved
the patients choosing their own top four worst symptoms and grad-
ing these on a visual analogue scale, it was not specified that these
symptoms had to be related to IBS, and details of the symptoms
patients chose were not reported are not given, hence this outcome
measure was not included in this review.
Peckham 2014 was a three armed trial that compared individu-
alised homeopathic treatment plus usual care to supportive listen-
ing plus usual care to usual care alone. Unequal randomisation
was used in Peckham 2014 with 16 participants allocated to indi-
vidualised homeopathic treatment, 18 to supportive listening and
60 to usual care. Individualised homeopathic treatment involved
a homeopathic consultation and an individualised homeopathic
remedy. Supportive listening aimed to control for the time and
attention given to the patient in the individualised homeopathic
treatment arm and consisted of the same number of sessions of the
same duration as the homeopathic consultation. In both the indi-
vidualised homeopathic treatment and supportive listening arms
patients were offered five one hour sessions with a homeopath
or counsellor respectively. The primary outcome measure in Peck-
ham 2014 was change in IBS-SSS at 6 months.
None of the included studies reported on adverse events as an out-
come.
Excluded studies
The Characteristics of excluded studies table, describes the charac-
teristics of the 32 excluded studies along with the reason for their
exclusion.
Ongoing studies
No ongoing studies were identified.
Risk of bias in included studies
The risk of bias in the included studies for each domain are dis-
cussed below. See results of the risk of bias analysis are summa-
rized in Figure 2.
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Figure 2.   Methodological quality summary: review authors' judgments about each methodological quality item for
each included study.
 
Allocation
Owen 1990, Rahlfs 1976, Rahlfs 1979 and Peckham 2014 were de-
scribed as RCTs. Owen 1990 reported that the participants were
stratified and randomised into one of two treatment groups. How-
ever, no details were given about the stratification or how randomi-
sation sequence was generated. Rahlfs 1976 reported that a chance
code was used for randomisation, although what this entailed and
how it was implemented was not described. Rahlfs 1979 did not
report any information regarding the method of generation of the
randomisation code. Peckham 2014 reported that the random se-
quence was generated by shuffling of sealed opaque envelopes
containing the allocation and was reported as being of low risk of
bias for allocation concealment. Rahlfs 1976 and Rahlfs 1979 pro-
vided medication in sequentially numbered drug containers and
were rated as low risk for allocation concealment. Owen 1990 did
not describe the procedure used for allocation concealment and
was rated as unclear for this item.
Blinding
Participants and physicians were not blinded to treatment alloca-
tion in the Owen 1990 and Peckham 2014 studies as it was not
possible to design a study where participants were not aware of
their receiving an individualised homeopathic consultation, sup-
portive listening or usual care. Owen 1990 did not report whether
other key study personnel were blinded, or whether outcome as-
sessment was carried out blind. In Peckham 2014 outcomes were
participant reported and due to participants being aware of their
allocation outcomes were at high risk of bias. In Rahlfs 1976 and
Rahlfs 1979 the study participants and the doctors who recruited
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the participants were blinded to allocation by the use of an iden-
tical placebo. In Rahlfs 1979, the participant blinding was well de-
scribed. Rahlfs 1976 and Rahlfs 1979 did not report whether other
key study personnel were blinded, or if outcome assessment was
carried out blind.
Incomplete outcome data
The number of patient withdrawals was reported for Owen 1990,
Rahlfs 1976, Rahlfs 1979 and Peckham 2014. Although Owen 1990
reported the number of withdrawals and the arm from which the
patients withdrew, the reasons for withdrawal were not reported.
In Peckham 2014 the reasons for withdrawal were reported and a
comparison of baseline data was made between those who had
missing data and those who did not, this indicated that there was
a relationship between age, employment status and missing data,
hence employment status and age were included in the ANCOVA
model for the primary outcome. Rahlfs 1976 did not report which
arms that patients withdrew from and therefore it was not clear
whether there may be attrition bias in this trial. Rahlfs 1979 report-
ed the number of withdrawals from each treatment group and the
reasons for withdrawal. Whilst dropouts appear to be comparable
in terms of number and reason for withdrawal across both arms of
this study (Rahlfs 1979), it should be remembered that any dropout
threatens group comparability at baseline as random allocation
seeks to distribute both known and unknown characteristics across
groups, and dropouts may differ for unknown characteristics that
cannot be measured.
Selective reporting
Due to insufficient reporting in Owen 1990 and Rahlfs 1976 both
studies were rated as unclear for the item on selective reporting.
Rahlfs 1979 was deemed to be at a high risk of bias due to selective
reporting because of evidence of selective choice of data for an out-
come. Some participants were excluded from the outcome analy-
ses for not meeting the inclusion criteria while other participants
who did not meet the inclusion criteria in terms of age were includ-
ed in the analyses. Peckham 2014 was deemed to be at low risk of
bias for selective reporting due to all the outcomes being reported
in the protocol paper being presented in the main paper.
Other potential sources of bias
Due to the low quality of reporting in Owen 1990, Rahlfs 1976 and
Rahlfs 1979, the potential for other sources of bias in these stud-
ies could not be assessed. No other potential sources of bias were
identified in Peckham 2014, however it cannot be certain that there
were no other sources of bias so this has been marked as unclear.
E>ects of interventions
See: Summary of findings for the main comparison Homeopathy
versus placebo; Summary of findings 2 Homeopathy versus usual
care; Summary of findings 3 Homeopathy plus usual care versus
usual care; Summary of findings 4 Homeopathy plus usual care
versus supportive listening plus usual care
Clinical homeopathic remedy versus placebo remedy
Rahlfs 1976 and Rahlfs 1979 assessed global improvement in IBS at
two weeks as an outcome measure. For this outcome patients were
asked to measure their improvement on a three-point scale (Rahlfs
1976) and a four-point scale (Rahlfs 1979). For the Rahlfs 1976 study
participants were asked to rate whether they were not or negligi-
bly improved, more than half improved or free of symptoms. Par-
ticipants in the Rahlfs 1979 study were asked to rate whether they
were worse, not or negligibly improved, more than half improved or
free of symptoms. For the purposes of this review, we dichotomised
these scales into two categories: those who had improved (more
than half improved or free of symptoms) versus those who had not
improved (those who were worse, or not or negligibly improved).
At short term follow up of two weeks, a pooled analysis (129 partic-
ipants) indicated that there may be a benefit of the homeopathic
treatment asafoetida over placebo. At short-term follow up of two
weeks, the RR for global improvement in symptoms for asafoetida
versus placebo was 1.61 (95% CI 1.18 to 2.18; very low certainty ev-
idence). Little heterogeneity was detected for this comparison (I2 =
18%). For the study that compared homeopathic remedy (asafoeti-
da plus nux vomica) to placebo the RR was 1.31 (95% CI 0.80 to 2.15;
very low certainty evidence).
Homeopathic treatment versus usual care
In Owen 1990 participants (N = 20) were asked to rate how unwell
they felt before and after treatment. The effect of individualised
homeopathic treatment was uncertain. The mean global improve-
ment score (i.e. how unwell the participants felt - a lower score indi-
cates feeling more unwell) in the individualised homeopathic treat-
ment arm was 1.44 (SD 4.55) compared to 1.41 (SD 1.97) in the usu-
al care arm (MD 0.03, 95% CI -3.16 to 3.22; very low certainty evi-
dence).
Homeopathic treatment plus usual care versus usual care
In Peckham 2014 participants were asked to complete the IBS-SSS
at baseline and at 6 months. The effect of individualised homeo-
pathic treatment at 6 months was uncertain. In the individualised
homeopathic treatment plus usual care arm the mean IBS-SSS
score was 210.44 (SD 112.4) compared to 237.30 (SD 110.22) in the
usual care arm (MD -26.86, 95% CI -88.59 to 34.87; low certainty ev-
idence). A lower score indicates less severity of symptoms.
Homeopathic treatment plus usual care versus supportive lis-
tening plus usual care
In Peckham 2014 participants were asked to complete the IBS-SSS
at baseline and at 6 months. The effect of homeopathic treatment
compared to supportive listening was uncertain. At six months the
mean IBS-SSS score in the homeopathic treatment plus usual care
arm was 210.44 (SD 112.4) compared to 262.00 (SD 120.72) in the
supportive listening plus usual care arm (MD -51.56, 95% CI -129.94
to 26.82; very low certainty evidence). A lower score indicates less
severity of symptoms.
Secondary outcome measures
The secondary outcomes quality of life, abdominal pain, stool fre-
quency, stool consistency and adverse events were not reported
on in Rahlfs 1976, Rahlfs 1979 or Owen 1990. Quality of life using
the EQ-5D was reported on in Peckham 2014. The effect of individ-
ualised homeopathic treatment on quality of life was uncertain. In
the homeopathic treatment arm the mean EQ-5D visual analogue
score (VAS) at six months was 69.07 (SD 17.35) compared to 63.41
(SD 23.31) in the usual care arm (MD 5.66, 95% CI -4.69 to 16.01; low
certainty evidence). In the homeopathic treatment arm the mean
EQ-5D score at six months was 69.07 (SD 17.35) compared to 63.09
(SD 24.38) in the supportive listening arm (MD 5.98, 95% CI -8.13 to
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20.09; very low certainty evidence). A lower score indicates a worse
quality of life.
Pooling of results
Outcome data from the Owen 1990 study was not pooled with the
data from Rahlfs 1976 and Rahlfs 1979 because of heterogeneity
between the studies. The three studies investigated two different
types of homeopathy. For the same reason outcome data from
Peckham 2014 was not pooled with outcome data from Rahlfs 1976
and Rahlfs 1979. Owen 1990 and Peckham 2014 investigated the
effectiveness of individualised (classical) homeopathic treatment,
whilst Rahlfs 1976 and Rahlfs 1979 investigated clinical homeopa-
thy. The type of IBS investigated was also potentially different. In
the Owen 1990 and Peckham 2014 studies participants were di-
agnosed with IBS and no further information on type was given,
whilst the participants in Rahlfs 1976 and Rahlfs 1979 had consti-
pation-predominant IBS. In addition, the studies measured out-
comes at different time points. Peckham 2014 measured outcomes
at 26 weeks and Owen 1990 measured outcomes at 12 weeks, whilst
Rahlfs 1976 and Rahlfs 1979 measured outcomes at 2 weeks. The
primary outcome for the Owen 1990 study was not a global im-
provement measure and was not comparable with the other three
studies. Although it may be tempting to combine studies in a meta-
analysis when it is likely to yield a statistically significant result, it is
important not to combine studies where there is significant clinical
heterogeneity, because these results would not be meaningful due
to the large degree of differences between the studies. For these
reasons the outcomes from Owen 1990, Peckham 2014, Rahlfs 1976
and Rahlfs 1979 were not combined.
D I S C U S S I O N
Summary of main results
Two RCTs compared a clinical homeopathic remedy (asafoetida
and asafoetida plus nux vomica) with placebo for treating IBS-C
(Rahlfs 1976; Rahlfs 1979). In a meta-analysis of these studies, the
homeopathic remedy found that there may be a benefit of the rem-
edy over placebo for improvement in global IBS symptoms at a
short-term follow-up of two weeks. However, this result should be
interpreted with caution due to the low quality of the reporting in
these studies, a high or unknown risk of bias associated with the
trials in this pooled analysis, short-term follow-up, and sparse data.
Two RCTs (Owen 1990; Peckham 2014) compared individualised
homeopathic treatment with usual care. In Owen 1990 individu-
alised homeopathic treatment was compared to usual care (dicy-
clomine hydrochloride, faecal bulking agents, and diet sheets ad-
vising a high fibre diet). No conclusions can be drawn from this
study due to the small number of participants, the low quality of re-
porting in this trial and a high risk of bias. Although Peckham 2014
has a low risk of bias and the quality of the reporting is good it is
difficult to draw conclusions from this study due to the small num-
ber of participants.
Overall completeness and applicability of evidence
Rahlfs 1976 and Rahlfs 1979 assessed the effectiveness of clinical
homeopathy for the treatment of constipation-predominant IBS.
Therefore this review does not provide information on the effec-
tiveness of clinical homeopathy for the treatment of IBS in general,
or diarrhoea-predominant, or mixed typology IBS. Both Rahlfs 1976
and Rahlfs 1979 reported outcomes at two weeks. Given the long
term nature of IBS it is not clear how useful a two-week outcome
is for patients', clinicians' and policy makers' decision making. As
people live with IBS for years, an evaluation of impact at two weeks
fails to take into account possible rebound effects or longer term
benefits or adverse events that would be important for patients and
practitioners to know about when they consider the potential ben-
efits and harms associated with this intervention.
Two studies that assessed the effectiveness of individualised
homeopathic treatment were identified in this review (Owen 1990;
Peckham 2014). The number of participants in both these studies
were small (N = 23 and N = 94 respectively). Owen 1990 was con-
ducted over 25 years ago. It is likely that there have been changes
in usual care for IBS since this time, therefore Owen 1990 may not
provide a full picture of the effectiveness of individualised homeo-
pathic treatment compared to usual care. Peckham 2014 was con-
ducted more recently and is likely to compare individualised home-
opathic treatment to current usual care however given the small
size of this study and the fact that it is underpowered makes it dif-
ficult to draw any firm conclusions from the study.
Quality of the evidence
The results from the pooled analysis indicate a possible benefit for
homeopathic treatment using clinical homeopathy (non-individu-
alised homeopathic remedies) over placebo for constipation-pre-
dominant IBS. However, this result needs to be interpreted with
caution. The two studies included in the pooled analysis (Rahlfs
1976 and Rahlfs 1979) were carried out in the 1970s before the in-
troduction of the CONSORT statement (Begg 1996), and the quali-
ty of reporting in these studies does not meet currently expected
standards (Schultz 2010). The low quality of the reporting means
that it is not possible to determine whether or not these studies
were carried out in a rigorous manner and thus how likely it is that
these results are a true reflection of the treatment effect. Both stud-
ies were determined to have an unknown risk of bias for most as-
sessed items and Rahlfs 1979 was at a high risk of reporting bias.
The quality of the evidence supporting the primary outcome (i.e.
global improvement) was very low due to the low quality of report-
ing in the included studies, high or unknown risk of bias, sparse da-
ta and short-term follow-up.
Participants in the Rahlfs 1976 and Rahlfs 1979 studies were recruit-
ed through general practice as having suspected IBS. It is not clear
whether diseases such as Crohn's disease or ulcerative colitis were
ruled out in these participants and it is possible that some partici-
pants had diseases such as Crohn's or ulcerative colitis rather than
IBS.
The quality of the reporting in the Owen 1990 study was low, and
this study does not meet the current expected standards (Schultz
2010). No conclusions can be drawn from this study due to the
small number of participants and risk of bias. Owen 1990 was rat-
ed as high risk of bias for blinding of participants and personnel.
The study was rated as unknown risk of bias for the other assessed
items. The exact details of the medication prescribed in the usual
care arm, in terms of dosage and frequency were not reported.
The quality of the reporting in the Peckham 2014 was good and
combined with the published protocol it meets the current expect-
ed standards (Schultz 2010). Peckham 2014 was rated as being at
low risk of bias for selection bias, attrition bias and reporting bias
and at high risk of bias for performance bias and detection bias.
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However the small number of participants in this study (n = 16
homeopathic treatment, n = 18 supportive listening and n = 60 usu-
al care) and the fact that it was underpowered mean no firm con-
clusions can be drawn from this study. The quality of the evidence
supporting the primary outcome (i.e. global improvement) ranged
from very low to low due to sparse data and high risk of bias.
Potential biases in the review process
To avoid potential biases in the review process data extraction was
carried out independently by two assessors. In addition, efforts
were made to identify all studies that were potentially eligible for
this review (see Search methods for identification of studies). How-
ever, It is possible that not all potentially eligible studies were iden-
tified. This could be because potentially eligible studies have been
carried out and then have not been published, or that studies have
been published but not in places where they could be accessed,
possibly because they were published in little known non-indexed
journals or they could have been published in places where they
should have been found, but were not found. One of the review au-
thors (EJP) was a trialist for an included study (Peckham 2014). For
this study, the assessment of risk of bias and data extraction was
performed by other authors. Cohort and case-control studies were
considered for inclusion but none were identified by the literature
search. In retrospect the inclusion of case-control studies was not
appropriate given that the main reason for including case-control
studies in a review is when an event is very rare and thus it is un-
likely that any RCTs have been carried out (Reeves 2011).
Agreements and disagreements with other studies or
reviews
No other systematic reviews of homeopathic treatment for IBS
were identified. However non-condition specific systematic re-
views of homeopathic treatment that included the Rahlfs 1976 and
Rahlfs 1979 studies have been published (Linde 1997; Shang 2005).
Neither of these systematic reviews carried out any analyses on
homeopathy for the treatment of IBS or specifically commented on
homeopathy for IBS.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The results for the outcomes assessed in this review are uncertain.
Thus no firm conclusions regarding the effectiveness and safety of
homeopathy for the treatment of IBS can be drawn.
In this review of homeopathic treatment for IBS, two of the includ-
ed studies used clinical (non-individualised) homeopathic reme-
dies to treat patients with constipation-predominant IBS (Rahlfs
1976; Rahlfs 1979). A meta-analysis of these two studies found a
possible benefit favouring the homeopathic remedy over placebo.
However, these results should be interpreted with caution due to
the low quality of reporting in these studies, a high or unknown
risk of bias and sparse data. Thus it is not possible to be certain
whether or not the trials were able to distinguish between true
treatment effects, chance or bias. Furthermore, the low quality of
reporting practice means that it is difficult to assess whether the re-
sults would be replicated in everyday practice, that is, whether the
results are externally valid or generalisable. We are therefore very
uncertain about these results and cannot suggest a possible bene-
fit for clinical homeopathy.
It is of note that Rahlfs 1976 and Rahlfs 1979 reported outcomes at
two weeks. Given the long term nature of IBS, it is not clear how use-
ful a two-week outcome is for decision making. It is essential that
trials have a follow-up period that is clinically meaningful. As peo-
ple live with IBS for years, an evaluation of impact at two weeks fails
to take into account any possible rebound effects, or longer term
benefits or adverse events that would be important for patients and
practitioners to know about when they consider the potential ben-
efits and harms associated with this intervention.
The results from Owen 1990 are uncertain and no conclusions can
be drawn from this study. Owen 1990 compared individualised
homeopathic treatment and usual care consisting of dicyclomine
hydrochloride and faecal bulking agents. The results from Peck-
ham 2014 are uncertain and no conclusions can be drawn from this
study. Peckham 2014 compared individualised homeopathic treat-
ment plus usual care, supportive listening plus usual care and usu-
al care. Individualised homeopathy is the most common form of
homeopathy practised in the UK. However due to the poor quality
of reporting in Owen 1990 study and the small number of partici-
pants in both Owen 1990 and Peckham 2014, no conclusions can
be made regarding the usefulness of individualised homeopathic
treatment for the treatment of IBS.
None of the included studies reported on adverse events therefore
no conclusions can be drawn on the safety of homeopathic treat-
ment for IBS.
Implications for research
Further high quality, adequately powered RCTs are required to as-
sess the efficacy and safety of clinical and individualised homeopa-
thy for IBS compared to placebo or usual care.
Rahlfs 1976 and Rahlfs 1979 evaluated clinical homeopathy involv-
ing pre-specified homeopathic remedies for the treatment of IBS-C
and were therefore designed to assess the effectiveness of non-in-
dividualised homeopathic remedies. However due to the high risk
of reporting bias in one of these studies and unclear reporting in
both of these studies it is recommended that these trials are repeat-
ed using current reporting guidelines (Schultz 2010), to determine
whether or not there is any benefit associated with homeopathy for
IBS. Future high quality studies should enrol larger numbers of pa-
tients and assess longer term efficacy and safety outcomes.
Owen 1990 assessed the effectiveness of individualised homeo-
pathic treatment compared to usual care and Peckham 2014 as-
sessed the effectiveness of individualised homeopathic treatment
plus usual care to usual care. Due to the low quality reporting in
Owen 1990 and the likelihood that usual care for IBS has changed
since this study was conducted, and the fact that Peckham 2014
was underpowered to detect a significant difference, it is recom-
mended that the effectiveness and safety of individualised homeo-
pathic treatment be evaluated in a well-designed, adequately pow-
ered trial.
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Characteristics of included studies [ordered by study ID]
 
Methods RCT, unblinded, parallel study, 12 weeks duration
Participants Setting; county hospital, UK
Number of participants; 23 patients were allocated into one of the treatment groups, 20 patients in-
cluded in analysis
Recruitment methods; female patients attending the out-patient department at a county hospital in
whom a diagnosis of IBS was made
Diagnosis of IBS; clinical diagnosis by a consultant gastroenterologist and consultant gynaecologist
Age range of patients; 20-69 years
Gender (of treated patients); 100% female
Duration of symptoms > 3 months
Interventions 1. Individualised homeopathic treatment
2. High doses of Dicyclomine hydrocholoride (exact dose not stated), faecal bulking agents and diet
sheets advising a high fibre diet
Outcomes Patients were asked to grade: their four worst symptoms on a visual analogue scale, dysmenorrhoea,
dyspareunia, and feeling unwell at baseline, 2, 6 and 12 weeks
Notes Detailed information is given on the homeopathic treatment the participants received in terms of; rem-
edy chosen, potency and dosage, whilst no information is given on the strength and dosage of the dicy-
clomine hydrocholoride and faecal bulking agents prescribed in the usual care arm
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Although it is stated that this is a randomised trial no details were given as to
how randomisation was achieved
Allocation concealment
(selection bias)
Unclear risk Not described
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient reporting of attrition, whilst possible reasons for attrition were dis-
cussed for one patient, the reasons for the other two patients leaving the study
were not reported
Selective reporting (re-
porting bias)
Unclear risk Insufficient information is provided to be able to judge whether the study is at
risk from selective reporting
Other bias Unclear risk Due to the low quality of the reporting in this study it is unclear whether the
study is at risk from any other forms of bias
Blinding of participants
and personnel (perfor-
mance bias) 
High risk Participants and doctors were not blinded to allocation, however it is not stat-
ed whether other key study personnel were blinded
Owen 1990 
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk It is not reported whether or not the outcome assessment was carried out
blind
Owen 1990  (Continued)
 
 
Methods Three arm, parallel group non-blinded randomised controlled trial 26 weeks in duration
Participants Setting: Hospital outpatient, UK
Number of participants; 94 patients were allocated into one of the treatment groups in a 4:1:1 ratio, 60
patients were allocated to usual care, 16 were offered homeopathic treatment plus usual care and 18
were offered supportive listening plus usual care
Recruitment methods; GP database recruitment, consultant gastroenterologist in secondary care
Diagnosis of IBS; diagnosed according to the Rome III criteria, potentially eligible participants were
asked to complete a questionnaire which included the Rome III criteria for IBS. Participants had to
score a minimum of 100 on the IBS-SSS to be eligible to take part in the trial
Mean age range of participants; 49 years
Gender; 83% female
Duration of symptoms > 3 months
Interventions 1. Individualised homeopathic treatment plus usual care
2. Supportive listening plus usual care
3. Usual care
Outcomes IBS-SSS, EQ-5D, HADS
Notes This study employed a Trials Within Cohorts design which recruited a cohort of people with IBS. From
this cohort people were randomly selected to receive the offer of a treatment.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random sequence generated by shuffling of sealed opaque envelopes con-
taining the allocation (protocol paper)
Allocation concealment
(selection bias)
Low risk Questionnaires from participants consenting and meeting the eligibility crite-
ria are taken one at a time, at the same time a sealed opaque envelope con-
taining the allocation is taken from the top of the shuffled pack and opened
and the allocation noted. This is carried out by an independent administrator
at the University of Sheffield, in the presence of another independent adminis-
trator. (protocol paper).
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk The proportion of patients who dropped out of the usual care and supportive
listening arms was similar and the reasons for dropping out were the same in
both groups.
9/60 (15%) participants in the usual care arm did not return the follow-up
questionnaire
Peckham 2014 
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All 16 participants in the homeopathy arm were included in the analysis
3/18 (17%) participants in the supportive listening arm did not return the
questionnaire
Selective reporting (re-
porting bias)
Low risk Outcome data presented for those outcome measures stated in the protocol.
Other bias Low risk The quality of reporting in this study was good and did not indicate that there
were likely to be other forms of bias.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Neither the nature of the interventions in this study nor the study design al-
lows for the masking of the therapists or the participants.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcomes were patient-reported outcomes (i.e. the patient was the outcome
assessor). As the patients were aware of the group allocation, this domain was
judged as high risk of bias.
Peckham 2014  (Continued)
 
 
Methods RCT, double blind, parallel study, 2 weeks duration
Participants Setting; general practice, Germany
Number of participants; 71 patients treated (number of patients randomised not clearly stated), 63 pa-
tients included in analysis
Recruitment methods; patients presenting in general practice with suspected IBS
Diagnosis of IBS; Clinical diagnosis plus completion of detailed questionnaire
Mean age (of treated patients); 43.8 years
Gender (of treated patients); 50.8% female
Duration of symptoms > 14 days
Interventions 1. 0.1% asafoetida alcohol solution, 6 x 5 drops daily
2. 0.1% asafoetida alcohol solution + 0.01% nux vomica alcohol solution, 6 x 5 drops daily
3. placebo, 45% alcohol solution, 6 x 5 drops daily
Outcomes Self assessment on a 3 point scale; no or negligible improvement, more than half improved, free of
symptoms measured on day 8 and day 15 of the study
Time to recovery assessed by the patient reporting the day they felt considerable improvement
Freiburg Personality Inventory
Notes Analysed participant data were fairly well described, but a lot of pre-randomisation and pre-analysis
data were missing
Risk of bias
Bias Authors' judgement Support for judgement
Rahlfs 1976 
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Random sequence genera-
tion (selection bias)
Unclear risk A chance code was used for the randomisation, the exact nature of which was
not reported
Therefore the risk of bias cannot be determined
Allocation concealment
(selection bias)
Low risk Medication was provided in sequentially numbered drug containers
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Insufficient reporting of attrition, some reasons for attrition are given, details
of allocation are not always given
Selective reporting (re-
porting bias)
Unclear risk Insufficient information was provided to be able to judge whether the study
was at risk from selective reporting
Other bias Unclear risk Insufficient information was provided to assess whether the study was at risk
from any other bias
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Study participants and recruiting doctors were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk It was not reported whether outcome assessment was carried out blind
Rahlfs 1976  (Continued)
 
 
Methods RCT, double blind, parallel study, 2 weeks duration
Participants Setting; general practice, Germany
Number of participants; 119 patients treated (number of participants randomised not clearly stated),
89 patients included in analysis
Recruitment methods; patients presenting in general practice with suspected IBS
Diagnosis of IBS; Clinical diagnosis plus completion of detailed questionnaire
Mean age (of patients included in analysis, ages of those not included not stated); 42.5 years
Gender (of those included in analysis, gender of those not included not stated); 68.5% female
Duration of symptoms > 14 days
Interventions 1. 0.1% asafoetida alcohol solution, 6 x 5 drops daily
2. placebo, 45% alcohol solution, 6 x 5 drops daily
Outcomes Self assessment on a 4 point scale; worsening of symptoms, no or negligible improvement, more than
half improved, free of symptoms, measured on day 8 and day 15 of the study
Time to recovery assessed by the patient reporting the day they felt considerable improvement
Notes Analysed participant data were fairly well described, but a lot of pre-randomisation and pre-analysis
data were missing
Rahlfs 1979 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Although it was reported that this was a randomised trial no details were given
as to how randomisation was achieved
Allocation concealment
(selection bias)
Low risk Medication was provided in sequentially numbered drug containers
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Incomplete outcome data, reasons for missing data, and how incomplete out-
come data were addressed was not clearly described
Selective reporting (re-
porting bias)
High risk The inclusion and exclusion criteria were applied in a variable manner, some
people that were subsequently found not to meet the exclusion and inclusion
criteria were removed from the analysis
However people who did not meet the inclusion criteria for age, being too old
were still included in the analysis
This leaves the study at risk of bias due to selective reporting
Other bias Unclear risk Due to the low quality of the reporting it was unclear whether the study was at
risk from any other forms of bias
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Participants and doctors were blinded to allocation
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk It was not reported whether outcome assessment was carried out blind to
treatment allocation
Rahlfs 1979  (Continued)
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Aleem 2000 Discussion piece and not a randomised controlled trial, cohort or case-control study
Anonymous 2005 An initial reading of this Italian article revealed it to be discussing a meta analysis by Shang 2005
Therefore a full translation was not conducted
Anonymous 2009 Discussion piece and not a randomised controlled trial, cohort or case-control study
Bauer 2014 Case studies on the treatment of IBS and not a randomised controlled trial, cohort or case-control
study
Bhagat 2010 Case report (n = 1) of homeopathic treatment for IBS
Bhattacharjee 2010 The article was a discussion on the different homeopathic remedies used for the treatment of IBS
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Study Reason for exclusion
Chen 2015 A discussion on the use of complementary therapies for the treatment of functional gastrointesti-
nal disorders
Cherniack 2013 Not on IBS
Chimthanawala 2004 Case report (n = 2) of homeopathic treatment for IBS
Diamond 2005 A discussion on the use of complementary therapies for the treatment of gastroenterological prob-
lems
Elio 2014 Report on a series of patients attending a clinic. Not specific to IBS and not an RCT or case series
Feldhaus 2000 This was a discussion piece on the treatment of IBS
Gamble 2007 Discussion of a potentially new way of assessing and treating IBS, from a homeopathic perspective,
using two cases as an example
Gebhardt 1988 Discussion on homeopathic treatment for IBS, not a randomised controlled trial, cohort or case-
control study
Gray 1998 This study was a case series of 25 patients with no comparator group
Greeson 2008 Non-randomised observational study of outcomes for patients attending a integrative medical cen-
tre where homeopathy was only one of the treatments offered
Grundmann 2014 Review of treatments for IBS does not include homeopathy
Innes 2000 This study was a case series (n = 20) with no comparator group
Jagose 2004 Case report (n = 1) of homeopathic treatment for IBS
Jones 1996 A discussion of the homeopathic treatment of IBS, illustrated by three cases
Jones 1997 Discussion piece on homeopathic treatment of IBS
Jones 1999 Case report study of a woman with IBS treated with homeopathy
Krishendu 2010 A discussion of the different homeopathic remedies used for the treatment of IBS
Lobo 2000 Case report (n = 1) on homeopathic treatment of IBS
Master 2008 Discussion piece on homeopathy for IBS
Mohan 2006 Case report (n = 2) of IBS treated with homeopathy
Pawar 2015 A discussion on homeopathic remedies
Pinto 1999 A selection of case reports on homeopathic treatment for a variety of conditions
Pohl 2013 An overview of treatments for irritable bowel syndrome which does not include homeopathy
Slade 2003 Case report (n = 1) of homeopathic treatment of ulcerative colitis
Turner 2008 Discussion of homeopathic treatment of IBS, illustrated by eight case histories
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Study Reason for exclusion
White 1999 Discussion of homeopathic treatment for IBS, not a randomised controlled trial, cohort or case-
control study
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Homeopathy versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Homeopathy versus placebo 2   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Global improvement (Asafoetida
only)
2 129 Risk Ratio (M-H, Fixed, 95% CI) 1.61 [1.18, 2.18]
1.2 Global improvement (Asafoetida +
nux vom)
1 42 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.80, 2.15]
 
 
Analysis 1.1.   Comparison 1 Homeopathy versus placebo, Outcome 1 Homeopathy versus placebo.
Study or subgroup Homeopathy Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.1.1 Global improvement (Asafoetida only)  
Rahlfs 1976 14/21 12/23 39.17% 1.28[0.78,2.1]
Rahlfs 1979 32/42 18/43 60.83% 1.82[1.23,2.69]
Subtotal (95% CI) 63 66 100% 1.61[1.18,2.18]
Total events: 46 (Homeopathy), 30 (Placebo)  
Heterogeneity: Tau2=0; Chi2=1.22, df=1(P=0.27); I2=17.77%  
Test for overall effect: Z=3.04(P=0)  
   
1.1.2 Global improvement (Asafoetida + nux vom)  
Rahlfs 1976 13/19 12/23 100% 1.31[0.8,2.15]
Subtotal (95% CI) 19 23 100% 1.31[0.8,2.15]
Total events: 13 (Homeopathy), 12 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.07(P=0.28)  
Test for subgroup differences: Chi2=0.47, df=1 (P=0.49), I2=0%  
Favours placebo 1000.01 100.1 1 Favours homeopathy
 
 
Comparison 2.   Homeopathy versus usual care
Outcome or subgroup title No. of
studies
No. of par-
ticipants
Statistical method Effect size
1 Global improvement (feeling unwell) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Analysis 2.1.   Comparison 2 Homeopathy versus usual care, Outcome 1 Global improvement (feeling unwell).
Study or subgroup Homeopathy Usual care Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
Owen 1990 9 1.4 (4.6) 11 1.4 (2) 0.03[-3.16,3.22]
Favours usual care 42-4 -2 0 Favours homeopathy
 
 
Comparison 3.   Homeopathy plus usual care versus usual care
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Global improvement (IBS-SSS) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Quality of life 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
 
 
Analysis 3.1.   Comparison 3 Homeopathy plus usual care
versus usual care, Outcome 1 Global improvement (IBS-SSS).
Study or subgroup Homeopathy Usual care Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
Peckham 2014 16 210.4 (112.4) 60 237.3 (110.2) -26.86[-88.59,34.87]
Favours homeopathy 10050-100 -50 0 Favours usual care
 
 
Analysis 3.2.   Comparison 3 Homeopathy plus usual care versus usual care, Outcome 2 Quality of life.
Study or subgroup Homeopathy Usual care Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
Peckham 2014 16 69.1 (17.4) 60 63.4 (23.3) 5.66[-4.69,16.01]
Favours usual care 10050-100 -50 0 Favours homeopathy
 
 
Comparison 4.   Homeopathy plus usual care versus supportive listening plus usual care
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Global improvement (IBS-SSS) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Quality of life 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Analysis 4.1.   Comparison 4 Homeopathy plus usual care versus supportive
listening plus usual care, Outcome 1 Global improvement (IBS-SSS).
Study or subgroup Homeopathy Supportive listening Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
Peckham 2014 16 210.4 (112.4) 18 262 (120.7) -51.56[-129.94,26.82]
Favours homeopathy 10050-100 -50 0 Favours control
 
 
Analysis 4.2.   Comparison 4 Homeopathy plus usual care versus
supportive listening plus usual care, Outcome 2 Quality of life.
Study or subgroup Homeopathy Supportive listening Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
Peckham 2014 16 69.1 (17.4) 18 63.1 (24.4) 5.98[-8.13,20.09]
Favours control 10050-100 -50 0 Favours homeopathy
 
 
A P P E N D I C E S
Appendix 1. Search Strategies
Medline
1. Colonic disease*.mp
2. irritable bowel syndrome/
3. colonic diseases, functional/
4. irritable bowel/
5. irritable colon/
6. spastic colon/
7. functional bowel disease*.mp.
8. functional colonic disease*.mp.
9. or/1-8
10. homeopathy/
11. homeopath*.mp.
12. homoeopath*.mp.
13. alternative medicine*.mp.
14. or/10-13
15. 9 and 14
EMBASE
1. Colonic disease*.mp
2. irritable bowel syndrome/
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3. colonic diseases, functional/
4. irritable bowel/
5. irritable colon/
6. spastic colon/
7. functional bowel disease*.mp.
8. functional colonic disease*.mp.
9. or/1-8
10. homeopathy/
11. homeopath*.mp.
12. homoeopath*.mp.
13. alternative medicine*.mp.
14. or/10-13
15. 9 and 14
CENTRAL
#1 MeSH: [Irritable bowel syndrome] explode all trees
#2 Colonic disease*
#3 irritable bowel syndrome
#4 colonic diseases, functional
#5 irritable bowel
#6 irritable colon
#7 spastic colon
#8 functional bowel disease*
#9 functional colonic disease*
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 homeopathy
#12 homeopath*
#13 homoeopath*
#14 alternative medicine*
#15 #11 or #12 or #13 or #14
#16 #10 and #15
Cumulative Index to Nursing and Allied Health Literature (CINAHL)
1. (TI homeopathy or AB homeopathy) OR (TI homeopath* or AB homeopath*) OR (TI homoeopath* or AB homoeopath*) OR (TI alternative
medicine* of AB alternative medicine*)
2. (TI Irritable bowel syndrome or AB Irritable bowel syndrome) OR (TI Colonic disease* or AB Colonic disease*) OR (TI irritable colon or AB
irritable colon) OR (TI spastic colon or AB spastic colon) OR (TI functional bowel disease* or AB functional bowel disease*) OR (TI functional
colonic disease* or AB functional colonic disease*)
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Allied and Complementary Medicine Database (AMED)
1. Colonic disease*.mp
2. irritable bowel syndrome/
3. colonic diseases, functional/
4. irritable bowel/
5. irritable colon/
6. spastic colon/
7. functional bowel disease*.mp.
8. functional colonic disease*.mp.
9. or/1-8
10. homeopathy/
11. homeopath*.mp.
12. homoeopath*.mp.
13. alternative medicine*.mp.
14. or/10-13
15. 9 and 14
Clinical trials. Gov
1. Homeopathy and Irritable bowel syndrome
IBD specialized register
1. Irritable bowel syndrome and homeopath
2. Colonic diseases and homeopath
3. Functional bowel and homeopath
W H A T ' S   N E W
 
Date Event Description
31 August 2018 New search has been performed New search and one new study added
31 August 2018 New citation required but conclusions
have not changed
Updated review, no new conclusions
 
C O N T R I B U T I O N S   O F   A U T H O R S
EJP initiated, designed the study and drafted the protocol. EP, SB and GT, extracted the data and conducted the quality assessment. AA
and KC arbitrated. KC provided advice on meta analysis. KC, SB, GT and AA all commented on the review.
D E C L A R A T I O N S   O F   I N T E R E S T
EJP has contributed to the design and management of one of the included RCTs. EJP is a homeopath.
GT: None known.
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SB: None known.
KC: None known.
AA: None known.
S O U R C E S   O F   S U P P O R T
Internal sources
• University of Leeds, UK.
• Homeopathy Research Institute, UK.
• ScHARR, UK.
External sources
• No sources of support supplied
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Ferula;  Constipation  [therapy];  Dicyclomine  [therapeutic use];  Dietary Fiber  [therapeutic use];  Homeopathy  [*methods];  Irritable
Bowel Syndrome  [*therapy];  Phytotherapy  [methods];  Randomized Controlled Trials as Topic
MeSH check words
Adult; Female; Humans; Male
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